Neurofilament light chain (NFL) as a potential biomarker of neurodegenerative diseases has been studied in a number of studies. Thus, a comprehensive meta-analysis is warranted to assess NFL performance in neurodegenerative diseases.
Objective:
To assess the performance of NFL in blood and cerebrospinal fluid (CSF) as a biomarker for neurodegenerative diseases.
Methods:
A total of 36 studies with comparison of NFL level between individuals with neurodegenerative diseases and controls were retrieved from PubMed, Web of Science and Science Direct, and the ratio of means method and delta method based on the random-effect model were used to analyze the differentiation of NFL between patients and controls.
Results:
Differentiation of CSF NFL between patients with neurodegenerative diseases and controls showed significant results. Although a few studies on blood NFL available were included in the meta-analysis, the results still showed a distinct possibility that NFL could be a potential biomarker for neurodegenerative diseases. NFL levels were increased significantly in dementias, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, and Huntington’s disease. By contrast, NFL levels were not increased in Parkinson’s disease (PD), although they were increased significantly in PD-related disorders (multiple system atrophy and progressive supranuclear palsy).
Conclusions:
In our study, in addition to PD, NFL was suggested to be a global diagnostic biomarker for neurodegenerative diseases. Moreover, it could be used in differential diagnosis of PD and PD-related disorders. However, it was worth noting that NFL was not appropriate for diagnosis or differential diagnosis without clinical symptoms and other auxiliary examinations.
SchlaepferWW, LynchRG (1977) Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol74, 241–250.
XuZ, HendersonRD, DavidM, McCombePA (2016) Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One11, e0164625.
7.
SkillbackT, FarahmandB, BartlettJW, RosenC, MattssonN, NaggaK, KilanderL, ReligaD, WimoA, WinbladB, RosengrenL, SchottJM, BlennowK, EriksdotterM, ZetterbergH (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology83, 1945–1953.
8.
ConstantinescuR, ZetterbergH, HolmbergB, RosengrenL (2009) Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord15, 205–212.
9.
ConstantinescuR, MondelloS (2012) Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol3, 187.
10.
ZetterbergH (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron91, 1–3.
11.
WanX, WangW, LiuJ, TongT (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol14, 135.
12.
WhitingP, RutjesAW, DinnesJ, ReitsmaJ, BossuytPM, KleijnenJ (2004) Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess8, iii, 1–234.
13.
BossuytPM, ReitsmaJB, BrunsDE, GatsonisCA, GlasziouPP, IrwigLM, MoherD, RennieD, de VetHC, LijmerJG (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med138, W1–12.
14.
SheaBJ, GrimshawJM, WellsGA, BoersM, AnderssonN, HamelC, PorterAC, TugwellP, MoherD, BouterLM (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol7, 10.
15.
OlssonB, LautnerR, AndreassonU, OhrfeltA, PorteliusE, BjerkeM, HolttaM, RosenC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol15, 673–684.
16.
FriedrichJO, AdhikariNK, BeyeneJ (2008) The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol8, 32.
17.
DerSimonianR LN (1986) Meta-analysis in clinical trials. Control Clin Trials7, 177–188.
18.
ZetterbergH, SkillbackT, MattssonN, TrojanowskiJQ, PorteliusE, ShawLM, WeinerMW, BlennowK (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol73, 60–67.
19.
van EijkJJ, van EverbroeckB, AbdoWF, KremerBP, VerbeekMM (2010) CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis21, 569–576.
20.
SjogrenM, RosengrenL, MinthonL, DavidssonP, BlennowK, WallinA (2000) Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology54, 1960–1964.
Abu-RumeilehS, MomettoN, Bartoletti-StellaA, PolischiB, OppiF, PodaR, Stanzani-MaseratiM, CortelliP, LiguoriR, CapellariS, ParchiP (2018) Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J Alzheimers Dis66, 551–563.
30.
SkillbackT, MattssonN, BlennowK, ZetterbergH (2017) Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener18, 397–403.
31.
MeeterLHH, VijverbergEG, Del CampoM, RozemullerAJM, Donker KaatL, de JongFJ, van der FlierWM, TeunissenCE, van SwietenJC, PijnenburgYAL (2018) Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology90, e1231–e1239.
32.
GaianiA, MartinelliI, BelloL, QuerinG, PuthenparampilM, RuggeroS, ToffaninE, CagninA, BrianiC, PegoraroE, SoraruG (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol74, 525–532.
33.
Abu-RumeilehS, CapellariS, Stanzani-MaseratiM, PolischiB, MartinelliP, CaroppoP, LadoganaA, ParchiP (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther10, 3.
34.
HerbertMK, AertsMB, BeenesM, NorgrenN, EsselinkRA, BloemBR, KuiperijHB, VerbeekMM (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol6, 91.
35.
HanssonO, JanelidzeS, HallS, MagdalinouN, LeesAJ, AndreassonU, NorgrenN, LinderJ, ForsgrenL, ConstantinescuR, ZetterbergH, BlennowK (2017) Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology88, 930–937.
36.
HallS, SurovaY, OhrfeltA, BlennowK, ZetterbergH, HanssonO (2016) Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease. Mov Disord31, 898–905.
37.
BackstromDC, Eriksson DomellofM, LinderJ, OlssonB, OhrfeltA, TruppM, ZetterbergH, BlennowK, ForsgrenL (2015) Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol72, 1175–1182.
SteinackerP, HussA, MayerB, GrehlT, GrosskreutzJ, BorckG, KuhleJ, LuleD, MeyerT, OecklP, PetriS, WeishauptJ, LudolphAC, OttoM (2017) Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener18, 112–119.
40.
WeydtP, OecklP, HussA, MullerK, VolkAE, KuhleJ, KnehrA, AndersenPM, PrudloJ, SteinackerP, WeishauptJH, LudolphAC, OttoM (2016) Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol79, 152–158.
MalmestromC, HaghighiS, RosengrenL, AndersenO, LyckeJ (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology61, 1720–1725.
43.
GunnarssonM, MalmestromC, AxelssonM, SundstromP, DahleC, VrethemM, OlssonT, PiehlF, NorgrenN, RosengrenL, SvenningssonA, LyckeJ (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol69, 83–89.
44.
SteinackerP, BlennowK, HalbgebauerS, ShiS, RufV, OecklP, GieseA, KuhleJ, SlivarichovaD, ZetterbergH, OttoM (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep6, 38737.
ConstantinescuR, RomerM, OakesD, RosengrenL, KieburtzK (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord15, 245–248.
47.
MattssonN, AndreassonU, ZetterbergH, BlennowK (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol74, 557–566.
48.
LinYS, LeeWJ, WangSJ, FuhJL (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep8, 17368.
49.
LewczukP, ErmannN, AndreassonU, SchultheisC, PodhornaJ, SpitzerP, MalerJM, KornhuberJ, BlennowK, ZetterbergH (2018) Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther10, 71.
RohrerJD, WoollacottIO, DickKM, BrotherhoodE, GordonE, FellowsA, ToombsJ, DruyehR, CardosoMJ, OurselinS, NicholasJM, NorgrenN, MeadS, AndreassonU, BlennowK, SchottJM, FoxNC, WarrenJD, ZetterbergH (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology87, 1329–1336.
52.
WilkeC, BenderF, HayerSN, BrockmannK, ScholsL, KuhleJ, SynofzikM (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol265, 1618–1624.
53.
RosengrenLE, KarlssonJE, SjogrenM, BlennowK, WallinA (1999) Neurofilament protein levels in CSF are increased in dementia. Neurology52, 1090–1093.
54.
DelbeuckX, Van der LindenM, ColletteF (2003) Alzheimer’s disease as a disconnection syndrome?Neuropsychol Rev13, 79–92.
55.
TerryRD, PeckA, DeTeresaR, SchechterR, HoroupianDS (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol10, 184–192.
56.
JellingerKA (2006) Clinicopathological analysis of dementia disorders in the elderly–an update. J Alzheimers Dis9, 61–70.
57.
BrunA (1987) Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr6, 193–208.
58.
ZhouL, MillerBL, McDanielCH, KellyL, KimOJ, MillerCA (1998) Frontotemporal dementia: neuropil spheroids and presynaptic terminal degeneration. Ann Neurol44, 99–109.
59.
NaganskaE, MatyjaE (2011) Amyotrophic lateral sclerosis – looking for pathogenesis and effective therapy. Folia Neuropathol49, 1–13.
